OB/GYN & Women's Health
Latest news
240 articles · 20 / page
Planetary Health Diet and Cardiometabolic Risk Reduction in Women with Gestational Diabetes: An Evidence-Based Review
This review synthesizes evidence linking adherence to the Planetary Health Diet with reduced risks of myocardial infarction, type 2 diabetes, and improved weight management in women post-gestational diabetes, highlighting BMI’s mediating ro
One Dose of HPV Vaccine Noninferior to Two: Implications for Global Cervical Cancer Prevention
A randomized trial of 20,330 girls 12–16 years shows one dose of bivalent or nonavalent HPV vaccine prevents persistent HPV16/18 infection as effectively as two doses over 5 years, with high effectiveness and no safety signals.
Genetic Liability to Hypertensive Disorders of Pregnancy Predicts Increased Long‑Term Cardiovascular Risk: Mendelian Randomization and Polygenic Risk Evidence
Genetic predisposition to preeclampsia and gestational hypertension is associated with higher risk of later-life cardiovascular disease; polygenic risk amplifies this risk, while obstetric history improves risk stratification beyond PRSs al
Elinzanetant: A Novel Non-Hormonal Neurokinin 1 and 3 Receptor Antagonist Transforming Menopausal Vasomotor Symptom Management
Elinzanetant, approved in the UK in July 2025 and by the FDA in October 2025, is the first non-hormonal NK1 and NK3 receptor antagonist for moderate-to-severe menopausal vasomotor symptoms, demonstrated effective and safe in pivotal phase 2
Elinzanetant for Menopausal Hot Flashes: A 52‑Week Phase 3 Trial Shows Modest, Durable Benefit and Acceptable Safety Profile
OASIS‑3 evaluated once‑daily oral elinzanetant 120 mg vs placebo for 52 weeks in postmenopausal women with moderate–severe vasomotor symptoms. At 12 weeks elinzanetant reduced daily moderate–severe VMS frequency by a least‑squares mean diff
Dapivirine Ring and Oral PrEP in Pregnancy: MTN-042/DELIVER Shows Infant Safety Through 12 Months
A randomized phase 3b trial found no infant safety signals attributable to in-utero exposure to the dapivirine vaginal ring or oral tenofovir–emtricitabine PrEP over 12 months of follow-up, supporting use of both options for HIV prevention
Hormonal Contraceptive Progestin Content Strongly Modifies Breast Cancer Risk in Adolescents and Premenopausal Women
A Swedish nationwide cohort (n≈2.1M) found small but measurable variation in breast cancer risk by hormonal contraceptive formulation—higher with desogestrel/etonogestrel products and lower with levonorgestrel-containing devices; absolute e
Global Gaps and Delays in Care for Breast, Cervical, and Ovarian Cancer: Insights from 275,792 Women in the VENUSCANCER Analysis
The VENUSCANCER secondary analysis of 275,792 records from 103 population-based registries reveals wide global variation in stage at diagnosis, concordance with guideline-recommended initial treatments, and time to treatment for breast, cer
Nationwide Prevention Programme in Australia Associated with Lower Preterm and Early‑Term Singleton Births: National and Hospital‑Level Results
A multifaceted national preterm birth prevention programme in Australia was associated with a modest national decrease in late preterm births and, after a hospital collaborative, a substantial reduction in early‑term births in participating
Blocking the Prolactin Receptor for Endometriosis Pain: HMI-115 Phase II Shows Dose-Dependent Analgesia Without Hypoestrogenic Effects
A multicenter phase II trial of HMI-115, a human monoclonal antibody against the prolactin receptor, showed dose-dependent reductions in endometriosis-associated pain and preserved ovarian function, supporting larger Phase III evaluation.
Long-Term Effectiveness of HPV Screen-and-Treat Strategy Versus Cytology in Cervical Cancer Screening: Insights from El Salvador’s CAPE Program
A 5-year follow-up study in El Salvador demonstrates that primary HPV screen-and-treat significantly reduces CIN2+ detection and HPV positivity compared to cytology, supporting extended screening intervals in low-resource settings.
Prophylactic Antibiotics in Episiotomy and Second Degree Tears: Insights from the REPAIR Trial
The REPAIR study demonstrates that prophylactic antibiotics reduce clinically relevant wound complications after episiotomy or second degree tears, highlighting a potential role for antibiotics in postpartum care.
Review for Cervical Cancer Screening
A comprehensive 2025 systematic review informing the Canadian Task Force finds cytology remains effective into the 60s, HPV-based strategies detect more precursors but increase colposcopy and false positives, and self-sampling improves upta
Trastuzumab Deruxtecan Plus Pertuzumab: A Promising First-Line Therapy for HER2-Positive Metastatic Breast Cancer
Trastuzumab deruxtecan combined with pertuzumab significantly improves progression-free survival over standard therapy in first-line HER2-positive metastatic breast cancer, offering enhanced response duration with manageable safety.
Behavioral Activation Reduces Perinatal Suicide Ideation: Insights from the SUMMIT Trial
A secondary analysis of the SUMMIT trial shows that brief behavioral activation therapy significantly reduces suicide ideation in perinatal women, regardless of clinician type or treatment modality, highlighting a scalable approach for suic
Early Diagnosis of Postpartum Haemorrhage: Insights from the E-MOTIVE Trial in Africa
This study nested within the E-MOTIVE trial reveals that using a lower blood loss threshold combined with clinical signs leads to earlier postpartum haemorrhage diagnosis and intervention, potentially reducing adverse outcomes in diverse Af
Advancing Treatment in Untreated Advanced Triple-Negative Breast Cancer: The Promising Role of Sacituzumab Govitecan
This review discusses a phase 3 trial demonstrating that sacituzumab govitecan improves progression-free survival in untreated, advanced triple-negative breast cancer patients not eligible for PD-1/PD-L1 inhibitors.
Innovative Oral SERD Plus Everolimus Therapy Shows Superior Efficacy in Advanced ER+ HER2- Breast Cancer
Roche announces positive phase 3 results of giredestrant plus everolimus, significantly reducing disease progression risk in ER+ HER2- advanced breast cancer patients post CDK4/6 inhibitor exposure, with favorable safety and promising survi
FDA Approves Bayer’s Lynkuet (Elinzanetant): A Novel Dual Neurokinin Receptor Antagonist for Menopausal Hot Flashes
Bayer’s Lynkuet (elinzanetant), a first-in-class dual neurokinin 1 and 3 receptor antagonist, has received FDA approval for treatment of moderate to severe menopausal vasomotor symptoms, demonstrating sustained efficacy and favorable safety
Browse by specialty
Open language-specific specialty feeds and department pages.